The global monoclonal antibodies market is expected to reach $148.9 billion by 2026, growing at a CAGR of 6.1%. Monoclonal antibodies are primarily used to treat cancer and other chronic diseases. The market is driven by an active drug development pipeline and increasing prevalence of diseases. Key players are focusing on developing biosimilars and targeting new disease areas to capitalize on market opportunities. The cancer segment currently dominates the market due to growing patient numbers and awareness. North America accounts for the largest share of the monoclonal antibodies market.

1. Monoclonal Antibodies (mAbs)
Market
Set to Exceed USD 148.9 Billion by 2026 | CAGR 6.1%
Forecast to 2020

2. Monoclonal Antibodies Market Size to Reach $148.9 Billion by 2026
- 2 -
“Global Monoclonal Antibodies (mAbs) Market [By Product Type (Fully Human,
Murine, Chimeric); By Production System (Mammalian Cell Culture, Microbial
Fermentation); By Indication (Cancer, Inflammation, Cardiovascular diseases,
Transplant Rejection, Respiratory and Infectious diseases); By Technology Platforms
(Transgenic-Mouse, Antibody Drug Conjugate, Phage-Display); By Target Mechanism
of Action (CGRP, HER2, CTLA4, TNF alpha, EGFR, VEGF, Anti CD, Anti IL, IgGs, PD-
1/PD-L1), By Care Delivery Setting (Primary and Specialty Care); By Routes of
Administration (Subcutaneous, Intravenous); By Drug Types (Branded Biologics,
Biosimilars), & By Region]: Market Size & Forecast, 2017 – 2026”
According to a new study published by Polaris Market Research the worldwide monoclonal antibodies
market is anticipated to reach over USD 148.9 billion by 2026. In 2017, by indication, the cancer
segment dominated the global market in terms of revenue; wherein fully-human monoclonal
antibodies held a major share of the market. In terms of geography, North America accounted for the
majority share in the global monoclonal antibodies market.
The monoclonal antibodies (mAbs) market is mainly driven by an active pipeline, wherein many
monoclonal antibodies are at the different stages of drug development. In addition, increased in
research and development, favorable government policies and rising prevalence of cancer and other
chronic diseases supplement the market growth. The other factors that augment that market growth
include the increasing the demand for personalized medicine and rising awareness among medical
professional and patients about the latest medical therapies. Moreover, emerging targets such as
central nervous system disorders, price correction and new delivery strategies for monoclonal
antibodies provide opportunities for market growth in the near future.
Browse Detailed Research Report On monoclonal antibodies (mAbs) market Analysis:
https://www.polarismarketresearch.com/industry-analysis/global-monoclonal-antibodies-
mabs-market
Monoclonal antibodies constitute a major share of the pharmaceutical market with several monoclonal
antibodies still in the pipeline. With over 30 monoclonal antibodies approved for use by regulatory
authorities, many monoclonal antibodies are in the pipeline at the pre-clinical stage and various stages
of clinical trials. Furthermore, availability of advanced technology for monoclonal antibodies
production has egged on many other market players to develop their own pipelines. Also, in the last
few years the patents of many monoclonal antibodies have expired thereby encouraging other
pharmaceutical companies to undertake production of monoclonal antibodies.

3. Monoclonal Antibodies Market Size to Reach $148.9 Billion by 2026
- 3 -
There has been an increase in the research and development activities in the field of monoclonal
antibodies. Several biomedical and technological advances in genetic engineering and next
generation genome sequencing have fuelled the growth of the monoclonal antibody market. Also,
multiple new targets have been identified during preclinical research, which has led to the
development and production of newer monoclonal antibodies by using various cytotechnological
methodologies. In addition to this, favorable government initiatives to enable cost-effective production
of monoclonal antibodies would give impetus to the monoclonal antibodies market growth. Also, pre-
defined guidelines by regulatory bodies would ensure the safe, effective and high quality
manufacturing of monoclonal antibodies Recently, the European Commission approved the first
biosimilar mAb Celltrion’s Truxima (biosimilar rituximab), thereby boding well for its potential approval
in the U.S.
Personalized medicine is being redefined by monoclonal antibodies that are the cutting-edge form of
immunotherapy. The surge in the demand for personalized medicine plays a crucial role in boosting
the monoclonal antibodies market by giving an impetus to the development of personalized drug
targets as every patient responds differently to different treatment regimens. Moreover, other factors
such as specificity, homogeneity and relatively fewer adverse events that entail usage of personalized
medicine contribute to significant market growth.
The widespread and rapidly increasing prevalence of cancer and other chronic diseases have resulted
in the soaring demand of biological medicines, thereby augmenting the growth of monoclonal
antibodies. Furthermore several other monoclonal antibodies used in treatment of deadly infections

4. Monoclonal Antibodies Market Size to Reach $148.9 Billion by 2026
- 4 -
such as HIV/AIDS, Ebola and Zika viral disease are in various phases of clinical trials. Also, high
spending power of patients in developed countries, increasing disposable incomes in developing
countries and better healthcare facilities further facilitate market growth. Going forward, increasing
awareness about the latest medical therapies among medical professional and patients, and
increasing utilization of monoclonal antibodies in treatment regimens is anticipated to propel the
market growth.
Based on indication, the global monoclonal antibodies market is segmented in to cancer,
inflammation, cardiovascular diseases, transplant rejection, respiratory and infectious diseases. The
cancer segment is expected to lead the market during the forecast period owing to rapidly expanding
patient pool, awareness about monoclonal antibodies among physicians and patients, improving
medical facilities, high spending power in developed countries and increasing disposable incomes in
developing countries.
The leading companies operating in this industry include Pfizer, Inc., GlaxoSmithKline PLC, Novartis
AG, Merck & Co., Inc., Eli Lily & Co., AstraZeneca, Amgen, Inc., Abbott Laboratories, Thermo Fisher
Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company, Ltd., Bayer AG,
Hoffmann-La Roche Ltd., and Novo Nordisk A/S. The market players have adopted various strategies
such as novel product development, new product release, and venture capital investments among
others to establish a foothold in the market and increase their customer base.
Request for sample:https://www.polarismarketresearch.com/industry-analysis/global-
monoclonal-antibodies-mabs-market/request-for-sample
Table of Contents
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-away
1.5. Stakeholders
2. Executive Summary
2.1. Market definition
2.2. Market segmentation
3. Monoclonal Antibodies Market Insights
3.1. Monoclonal Antibodies – Industry snapshot
3.2. Monoclonal Antibodies - Ecosystem analysis
3.3. Monoclonal Antibodies Market Dynamics
3.3.1. Monoclonal Antibodies – Market Forces
3.3.1.1. Monoclonal Antibodies Market Driver Analysis

5. Monoclonal Antibodies Market Size to Reach $148.9 Billion by 2026
- 5 -
3.3.1.2. Monoclonal Antibodies Market Restraint/Challenges analysis
3.3.1.3. Monoclonal Antibodies Market Opportunity Analysis
3.3.2. Industry analysis - Porter's five forces
3.3.2.1. Bargaining power of supplier
3.3.2.2. Bargaining power of buyer
3.3.2.3. Threat of substitute
3.3.2.4. Threat of new entrant
3.3.2.5. Degree of competition
3.3.3. Monoclonal Antibodies Market PEST Analysis, 2017
3.3.4. Monoclonal Antibodies Market Value Chain Analysis
3.3.5. Monoclonal Antibodies Industry Trends
3.3.6. Competitive Ranking Analysis
4. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Product Type
4.1. Key Findings
4.2. Fully Human
4.3. Murine
4.4. Chimeric
4.5. Humanized
5. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Production
System
5.1. Key Findings
5.2. Mammalian Cell Culture
5.3. Microbial Fermentation
6. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Indication
6.1. Key Findings
6.2. Cancer
6.3. Inflammation
6.4. Cardiovascular diseases
6.5. Transplant Rejection
6.6. Respiratory
6.7. Infectious diseases
7. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Technology
Platforms
7.1. Key Findings
7.2. Transgenic-Mouse
7.3. Antibody Drug Conjugate
7.4. Phage-Display
8. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Target
Mechanism of Action
8.1. Key Findings
8.2. CGRP
8.3. HER2
8.4. CTLA4
8.5. TNF alpha
8.6. EGFR
8.7. VEGF
8.8. Anti CD
8.9. Anti-IL
8.10. IgGs, PD-1/PD-L1
9. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Care Delivery
Setting
9.1. Key Findings

6. Monoclonal Antibodies Market Size to Reach $148.9 Billion by 2026
- 6 -
9.2. Primary
9.3. Specialty Care
10. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Route of
Administration
10.1. Key Findings
10.2. Subcutaneous
10.3. Intravenous
11. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Drug Types
11.1. Key Findings
11.2. Branded Biologics
11.3. Biosimilars
12. Monoclonal Antibodies Testing Market Size and Forecast, 2017-2026 by Region
12.1. Key Findings
12.2. North America
12.2.1.U.S.
12.2.2.Canada
12.3. Europe
12.3.1.UK
12.3.2.Germany
12.3.3.Rest of Europe
12.4. Asia-Pacific
12.4.1.China
12.4.2.Japan
12.4.3.India
12.4.4.Rest of Asia-Pacific
12.5. Latin America
12.5.1.Brazil
12.5.2.Mexico
12.6. Middle East & Africa
12.6.1.South Africa
12.6.2.Rest of Middle East & Africa
13. Company Profiles
13.1. Pfizer, Inc.,
13.1.1.Overview
13.1.2.Financials
13.1.3.Product Benchmarking
13.1.4.Recent Developments
13.2. GlaxoSmithKline PLC
13.2.1.Overview
13.2.2.Financials
13.2.3.Product Benchmarking
13.2.4.Recent Developments
13.3. Novartis AG
13.3.1.Overview
13.3.2.Financials
13.3.3.Product Benchmarking
13.3.4.Recent Developments
13.4. Merck & Co., Inc.
13.4.1.Overview
13.4.2.Financials
13.4.3.Product Benchmarking
13.4.4.Recent Developments

7. Monoclonal Antibodies Market Size to Reach $148.9 Billion by 2026
- 7 -
13.5. Eli Lily & Co.
13.5.1.Overview
13.5.2.Financials
13.5.3.Product Benchmarking
13.5.4.Recent Developments
13.6. AstraZeneca
13.6.1.Overview
13.6.2.Financials
13.6.3.Product Benchmarking
13.6.4.Recent Developments
13.7. Amgen, Inc.
13.7.1.Overview
13.7.2.Financials
13.7.3.Product Benchmarking
13.7.4.Recent Developments
13.8. Abbott Laboratories
13.8.1.Overview
13.8.2.Financials
13.8.3.Product Benchmarking
13.8.4.Recent Developments
13.9. Thermo Fisher Scientific, Inc.
13.9.1.Overview
13.9.2.Financials
13.9.3.Product Benchmarking
13.9.4.Recent Developments
13.10. Bistro-Myers Squibb.
13.10.1. Overview
13.10.2. Financials
13.10.3. Product Benchmarking
13.10.4. Recent Developments
13.11. Mylan N.V.
13.11.1. Overview
13.11.2. Financials
13.11.3. Product Benchmarking
13.11.4. Recent Developments
13.12. Daiichi Sankyo Company, Ltd.
13.12.1. Overview
13.12.2. Financials
13.12.3. Product Benchmarking
13.12.4. Recent Developments
13.13. Bayer AG
13.13.1. Overview
13.13.2. Financials
13.13.3. Product Benchmarking
13.13.4. Recent Developments
13.14. Hoffmann-La Roche Ltd.
13.14.1. Overview
13.14.2. Financials
13.14.3. Product Benchmarking
13.14.4. Recent Developments
13.15. Novo Nordisk A/S
13.15.1. Overview

8. Monoclonal Antibodies Market Size to Reach $148.9 Billion by 2026
- 8 -
13.15.2. Financials
13.15.3. Product Benchmarking
13.15.4. Recent Developments
Access Press Release on Monoclonal Antibodies (mAbs) Market:
https://www.polarismarketresearch.com/press-releases/global-monoclonal-antibodies-mabs-
market
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company
specializes in providing exceptional market intelligence and in-depth business research services for
our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse
customer base present across the industries of healthcare, technology, semi-conductors and
chemicals among various other industries present around the world. We strive to provide our
customers with updated information on innovative technologies, high growth markets, emerging
business environments and latest business-centric applications, thereby helping them always to make
informed decisions and leverage new opportunities. Adept with a highly competent, experienced and
extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris
endeavor to deliver value-added business solutions to our customers.
E mail Id: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
Official Blog: http://healthcare-market-insights.blogspot.com/